MAP2K7 and colorectal carcinoma: Another study, using 14 as an MEK inhibitor, concluded that combined treatment with MEK, EGFR, and PD-L1 inhibitors may be a promising treatment option for a particular subtype of CRC patients [93] (Figure 3).